Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia. (20th October 2022)

• Record Type: Journal Article
• Authors: Pereira‐Martins, Diego A.; Coelho‐Silva, Juan L.; Weinhäuser, Isabel; Franca‐Neto, Pedro L.; Silveira, Douglas R.; Ortiz, César; Moreira‐Aguiar, Amanda; Lima, Marinus M.; Koury, Luisa C.; de Melo, Raul A.; Glória, Ana B.; Fagundes, Evandro M.; Lino, Bruno K.; Pagnano, Katia; Bittencourt, Rosane; Nunes, Elenaide; Traina, Fabiola; Figueiredo‐Pontes, Lorena; Keating, Armand; Tallman, Martin S.; Ribeiro, Raul C.; Dilon, Richard; Ganser, Arnold; Sanz, Miguel A.; Berliner, Nancy; Valk, Peter; Löwenberg, Bob; Ottone, Tiziana; Noguera, Nelida I.; Voso, Maria T.; Paoloni, Francesca; Fazi, Paola; Ammatuna, Emanuele; Huls, Gerwin; Schuringa, Jan Jacob; Rego, Eduardo M.; Lucena‐Araujo, Antonio R.;
• Is Part Of: British journal of haematology. Volume 200:Number 2(2023)
• Page Start: 170
• Page End: 174
• Publication Date: 2022-10-20
• Subjects: anthracycline‐based chemotherapy -- ATRA -- mtDNA content -- oxidative phosphorylation; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.18510
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. Here, we show that patients with higher‐than‐normal mtDNAc had better outcomes regardless of tumour burden. These results were more evident in patients with low‐risk of relapse. The multivariate Cox proportional hazard model demonstrated that high mtDNAc was independently associated with a decreased cumulative incidence of relapse. Altogether, our data highlights the possible role of mitochondrial metabolism in APL patients treated with ATRA.